Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Phase: N/A Priority: Normal
NCT ID: NCT03562637 Org: User:
Start: 12/05/18 End: 12/30/27 Due: 12/30/28

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02310464 Org: User:
Start: 12/22/15 End: 02/02/21 Due: 02/02/22

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06480240 Org: User:
Start: 06/12/24 End: 06/30/27 Due: 06/30/28

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05442060 Org: User:
Start: 07/27/22 End: 05/31/26 Due: 05/31/27

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT03573544 Org: User:
Start: 05/07/18 End: 04/07/22 Due: 04/07/23

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04084366 Org: User:
Start: 11/25/19 End: 10/27/23 Due: 10/27/24

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01516307 Org: User:
Start: 12/31/11 End: 08/31/19 Due: 08/31/20

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03592264 Org: User:
Start: 07/02/18 End: 03/21/24 Due: 03/21/25